Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440088 · ClinicalTrials.gov registry record · Phase 3
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
A Phase 3 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
NCT01440088: Completed Phase 3 study, sponsored by Threshold Pharmaceuticals.
NCT01440088 is a Phase 3 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 640 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01440088, a Phase 3 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
Primary Outcome
Efficacy will be determined by overall survival in subjects with locally advanced unresectable or metastatic soft tissue sarcoma previously untreated with chemotherapy compared with doxorubicin alone
Interventions
- DRUG Doxorubicin
- DRUG TH-302 in Combination with Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
What the finished NCT01440088 record still lists
NCT01440088 is an interventional study that assigns participants to a tested intervention. The registered 640 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT01440088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01440088 about?
NCT01440088 is a clinical study titled "A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma". The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
What is the current status of trial NCT01440088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2011-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01440088?
The interventions under investigation include: Doxorubicin (DRUG), TH-302 in Combination with Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT01440088?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01440088's enrollment target sits among peer trials
640 576th of 2000 higher than 1,422 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
- NCT05156398 · 640 participants · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- NCT05930483 · 640 participants · NA
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia